Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT02588612 · COMPLETED
Trial details
- NCT number
- NCT02588612
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2020-08-10
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.